Alexandre Lambert

6.1k total citations · 2 hit papers
27 papers, 2.6k citations indexed

About

Alexandre Lambert is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Alexandre Lambert has authored 27 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Genetics and 9 papers in Hematology. Recurrent topics in Alexandre Lambert's work include Cancer Immunotherapy and Biomarkers (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Alexandre Lambert is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Alexandre Lambert collaborates with scholars based in United States, Belgium and France. Alexandre Lambert's co-authors include Elizabeth R. Plimack, Arlene O. Siefker‐Radtke, Alex Azrilevich, Padmanee Sharma, Abdel Saci, Andrea Necchi, Matthew D. Galsky, Daniel A. Vaena, Sumanta K. Pal and Marc‐Oliver Grimm and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Alexandre Lambert

27 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Padmanee Sharma, Margitta Retz et al. The Lancet Oncology profile →
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

2014 865 citations Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexandre Lambert United States	12	1.8k	1.0k	702	579	372	27	2.6k
Suba Krishnan United States	14	1.8k 1.0×	1.3k 1.2×	453 0.6×	681 1.2×	446 1.2×	21	2.6k
Gina M. Vaccaro United States	20	1.2k 0.7×	1.1k 1.1×	833 1.2×	121 0.2×	494 1.3×	52	2.3k
G. Seipelt Germany	26	1.6k 0.9×	540 0.5×	1.2k 1.7×	402 0.7×	352 0.9×	75	3.0k
Thomas Powles United Kingdom	24	2.4k 1.3×	1.9k 1.9×	1.1k 1.6×	558 1.0×	649 1.7×	105	3.7k
Christophe Massard France	12	1.2k 0.7×	1.1k 1.1×	360 0.5×	340 0.6×	194 0.5×	30	1.8k
Christian Meyer zum Büschenfelde Germany	20	1.4k 0.8×	730 0.7×	1.1k 1.5×	284 0.5×	409 1.1×	31	2.4k
Zbigniew Nowecki Poland	26	1.6k 0.9×	512 0.5×	1.1k 1.5×	362 0.6×	510 1.4×	118	2.7k
Amy Harlow United States	9	537 0.3×	255 0.3×	692 1.0×	232 0.4×	442 1.2×	10	1.6k
Eray Goekkurt Germany	22	1.5k 0.8×	710 0.7×	992 1.4×	143 0.2×	416 1.1×	100	2.3k
Shuchi S. Pandya United States	19	980 0.5×	276 0.3×	900 1.3×	101 0.2×	895 2.4×	69	2.1k

Countries citing papers authored by Alexandre Lambert

Since Specialization

Citations

This map shows the geographic impact of Alexandre Lambert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandre Lambert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandre Lambert more than expected).

Fields of papers citing papers by Alexandre Lambert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandre Lambert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandre Lambert. The network helps show where Alexandre Lambert may publish in the future.

Co-authorship network of co-authors of Alexandre Lambert

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandre Lambert. A scholar is included among the top collaborators of Alexandre Lambert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandre Lambert. Alexandre Lambert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rabat, Arnaud, Jeroen Van Cutsem, Samuele Marcora, et al.. (2025). Fatigue and management of warfighter mental endurance. BMJ Military Health. 171(5). 447–451. 1 indexed citations

Lambert, Alexandre, Damien Léger, Mounir Chennaoui, et al.. (2023). Détection du degré de fatigue cognitive d’un visage par un évaluateur humain (étude CLAVIF). Médecine du Sommeil. 20(1). 46–46. 1 indexed citations

Legrand, Catherine, et al.. (2022). On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes. Pharmaceutical Statistics. 22(2). 284–299. 2 indexed citations

Sonpavde, Guru, Andrea Necchi, Shilpa Gupta, et al.. (2020). A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 38(15_suppl). TPS5091–TPS5091. 2 indexed citations

Hahn, Noah M., Sam S. Chang, Maxwell V. Meng, et al.. (2020). A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.. Journal of Clinical Oncology. 38(15_suppl). TPS5090–TPS5090. 9 indexed citations

Hahn, Noah M., Sam S. Chang, Maxwell V. Meng, et al.. (2019). A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.. Journal of Clinical Oncology. 37(7_suppl). TPS493–TPS493. 8 indexed citations

Péron, Julien, Alexandre Lambert, Stéphane Munier, et al.. (2019). Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. JNCI Journal of the National Cancer Institute. 111(11). 1186–1191. 15 indexed citations

Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2017). Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study. Annals of Oncology. 28. v296–v297. 49 indexed citations

Sharma, Padmanee, Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 18(3). 312–322. 1203 indexed citations breakdown →

10.

Galsky, Matt D., Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2016). Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. Annals of Oncology. 27. vi567–vi567. 23 indexed citations

11.

Agrawal, Shruti, Ian M. Waxman, Alexandre Lambert, Amit Roy, & Raymond B. Darbenzio. (2016). Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab. Cancer Chemotherapy and Pharmacology. 77(3). 635–641. 12 indexed citations

12.

Sharma, Padmanee, Marc‐Oliver Grimm, Matthew D. Galsky, et al.. (2015). A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

13.

Motzer, Robert J., Brian I. Rini, David F. McDermott, et al.. (2014). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 33(13). 1430–1437. 865 indexed citations breakdown →

14.

Weber, Jeffrey S., David R. Minor, Sandra P. D’Angelo, et al.. (2014). A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. Annals of Oncology. 25. v1–v1. 59 indexed citations

15.

Motzer, Robert J., Brian I. Rini, David F. McDermott, et al.. (2014). Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.. Journal of Clinical Oncology. 32(15_suppl). 5009–5009. 55 indexed citations

16.

Hochhaus, Andreas, Giuseppe Saglio, Charles Chuah, et al.. (2011). Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial. Blood. 118(21). 2767–2767. 18 indexed citations

17.

Saglio, Giuseppe, Jörge E. Cortes, CA Schiffer, et al.. (2010). Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.. Journal of Clinical Oncology. 28(15_suppl). 6569–6569. 2 indexed citations

18.

Shah, Neha, D.-W. Kim, Hagop M. Kantarjian, et al.. (2010). Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 95(2). 232–240. 180 indexed citations

19.

Hochhaus, Andreas, Martin C. Müller, Jerald P. Radich, et al.. (2009). Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 23(9). 1628–1633. 29 indexed citations

20.

Shah, Neil P., Erkut Bahceci, Alexandre Lambert, Lynn Ploughman, & Jerald P. Radich. (2009). Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).. Blood. 114(22). 1122–1122. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact